Henrik Ljung - SpectraCure Chief Officer
| SPEC Stock | SEK 1.58 0.04 2.47% |
Insider
Henrik Ljung is Chief Officer of SpectraCure AB
| Age | 65 |
| Phone | 46 46 16 20 70 |
| Web | https://www.spectracure.com |
SpectraCure Management Efficiency
The company has return on total asset (ROA) of (0.0851) % which means that it has lost $0.0851 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1471) %, meaning that it generated substantial loss on money invested by shareholders. SpectraCure's management efficiency ratios could be used to measure how well SpectraCure manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Cecilia Jungner | SolTech Energy Sweden | N/A | |
| Jorgen Drejer | Saniona AB | 68 | |
| Peter Selin | Kancera AB | 50 | |
| Magnus Ekblad | SaltX Technology Holding | N/A | |
| Bernardo Guterres | Maha Energy AB | 37 | |
| Paulo Mendonca | Maha Energy AB | 35 | |
| Eric Jacobson | SaltX Technology Holding | N/A | |
| Thomas Olin | Kancera AB | 65 | |
| Karin Nielsen | Saniona AB | N/A | |
| Luciana Borges | Maha Energy AB | 45 | |
| Rami Levin | Saniona AB | 54 | |
| Hans Richter | Kancera AB | 74 | |
| Josefin Sollander | SolTech Energy Sweden | N/A | |
| Oscar Nelson | SolTech Energy Sweden | N/A | |
| Martin Norin | Kancera AB | 64 | |
| Niclas Brynne | Kancera AB | 62 | |
| MBA MSc | Saniona AB | 63 | |
| Lars Croon | SaltX Technology Holding | N/A | |
| Alan BE | Maha Energy AB | 52 | |
| Niclas Lundin | SolTech Energy Sweden | N/A | |
| Stefan Krafft | SaltX Technology Holding | N/A | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0851 |
SpectraCure AB Leadership Team
Elected by the shareholders, the SpectraCure's board of directors comprises two types of representatives: SpectraCure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SpectraCure. The board's role is to monitor SpectraCure's management team and ensure that shareholders' interests are well served. SpectraCure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SpectraCure's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mirjam Johansson, Adm Mang | ||
| Kristina Holst, Head Affairs | ||
| Henrik Ljung, Chief Officer | ||
| Johannes Swartling, Technical Mang | ||
| Johan Folkunger, Chief Officer |
SpectraCure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SpectraCure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0851 | |||
| Operating Margin | (15.50) % | |||
| Current Valuation | 561.51 M | |||
| Shares Outstanding | 97.13 M | |||
| Shares Owned By Insiders | 21.26 % | |||
| Shares Owned By Institutions | 5.95 % | |||
| Price To Book | 4.21 X | |||
| Price To Sales | 396.86 X | |||
| Revenue | 5.75 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SpectraCure Stock Analysis
When running SpectraCure's price analysis, check to measure SpectraCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpectraCure is operating at the current time. Most of SpectraCure's value examination focuses on studying past and present price action to predict the probability of SpectraCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpectraCure's price. Additionally, you may evaluate how the addition of SpectraCure to your portfolios can decrease your overall portfolio volatility.